Contents | Next article | Previous article
Journal 'Cytokines & inflammation', 2003, No. 2
|
Original Articles
|
Number 2'2003
|
BETALEUKIN (RHIL-1) AS A PROTECTOR OF HAEMOPOIESIS IN PATIENTS RECEIVING INTENSIVE CHEMOTHERAPY
N.B. Mikhailova, S.A. Ketlinsky, A.S. Simbirtsev, A.Yu. Zaritsky, G.N. Sologub,
O.S. Pancratova, E.I. Darskaya, B.V. Afanasyev
The aim of the study was to evaluate the efficacy of recombinant human interleukin1 Betaleukin and its possible role as a protective agent and haemopoesis stimulator in patients receiving intensive chemotherapy (CT). 2 schemes of treatment were compared; according to one of them Betaleukin was administered subcutaneously 24 hours before the beginning of CT; the dose of Betaleukin was 8-10 ng/kg. According to the second scheme, Betaleukin was administered intravenously during 1-6 days after autologous haemopoietic stem cells transplantation (AHSCT); the dose was 4,5-15 ng/kg. All patients were divided in 2 groups: the patients, receiving CT without AHSCT and those treated by high-dose CT with AHSCT. Two control groups received the same treatment as the main ones without Betaleukin. In group 1 leucocytes recovery (leucocytes " 1x109/l) occured on day 1,3 + 0,7 vs 5.5 + 1.7 in control group (p = 0,01) and neutrophil reconstitution (" 0,5x109/l) was observed on day 3,0 + 1,1 vs 6,2 + 1,4 (p = 0.03). No significant differences were revealed in second group in comparison to controls. No severe complications were observed after Betaleukin treatment; the majority of patients had fever and local skin hyperemia at the site of the injection. Conclusion: Betaleukin in dose 8-10 ng/kg of body weight was well tolerated and revealed protective effect on haemopoiesis in patients receiving non-myeloablative CT.
Keywords: interleukin-1, haemopoietic protection, chemotherapy.
Contents | Next article | Previous article
|
|
![[About us] Journal 'Cytokines & Inflammation'](/images/Logo.gif){kind=logo}
